Navigation Links
Neuro Kinetics Invited to Present at NIH Forum for Investors and Strategic Partners
Date:2/14/2012

PITTSBURGH, Feb. 14, 2012 /PRNewswire/ -- Neuro Kinetics, Inc. (NKI) (www.neuro-kinetics.com), manufacturers and marketers of noninvasive medical diagnostic equipment used worldwide for neurophysiologic/ neurotologic testing, said today that it is presenting at the National Institutes of Health's (NIH) Feedback Sessions in Washington D.C. on February 28, 2012.

The Feedback Sessions are an invitation only program funded by the NIH in cooperation with the Larta Institute (www.larta.org) called the SBIR Commercialization Assistance Program (CAP).  CAP exposes some of the nation's most promising small life science and healthcare companies and their technologies and business strategies to the investment community, strategic partners and licensees. 

NKI, with assistance from NIH and Larta, is presenting to investors, life science professionals and consultants, and corporate development officers at 8:30 Tuesday morning the 28th. 

"NKI is honored to be one of only forty companies selected to participate," said Vince Kytka, Director of Operations and Marketing. "This program is a great opportunity for accelerating our path to market."

NKI, poised for exciting growth, has had promising success with its I-Portal® technology to diagnose concussions, and, with the support of NIH's SBIR program, it is progressing in the development of its revolutionary I- Portal® Retinopathy product, a new, non-invasive ophthalmic diagnostic device. Initial data suggests this tool can provide early detection of diabetic retinopathy. 

"We are looking forward to this great opportunity to share our progress and potential with such a knowledgeable and influential group," added Howison Schroeder, President and CEO.

Admission to the sessions are limited and by invitation only. If you are interested in attending, please send your contact info to
'/>"/>

SOURCE Neuro Kinetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Iron-moving malfunction may underlie neurodegenerative diseases, aging
2. Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology
3. Stabilizing force for good communication between neurons and muscle cells found
4. Researchers identify promising gene target for neuroblastoma therapy
5. How neuronal activity leads to Alzheimers protein cleavage
6. Mediator in communication between neurons and muscle cells found
7. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
8. A double-barreled immune cell approach for neuroblastoma
9. Protecting neurons could halt Alzheimers, Parkinsons diseases
10. Neuroinformatics special issue spotlights the Neuroscience Information Framework
11. Bipolar disorder genes, pathways identified by Indiana University neuroscientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... and the bees. But that old expression leaves ... fertilization process for flowering plants is particularly complex ... female reproductive cells. New research from an international ... including Carnegie,s Wolf Frommer, David Ehrhardt, and Guido ... that guides flowering plant fertilization. It is published ...
(Date:8/21/2014)... unknown process for harvesting energy and producing oxygen from ... University scientist has discovered. The discovery lays the foundation ... energy from the Sun, and understanding dense blooms like ... worldwide. A paper describing the discovery will be published ... journal Science on 21 August 2014. , ...
(Date:8/21/2014)... Nine researchers from Beth Israel Deaconess Medical Center (BIDMC ... World,s Most Influential Scientific Minds 2014," a comprehensive ... a web resource for science metrics and research performance ... the most influential "are performing and publishing work that ... their science," according to a Thomson Reuters statement. Researchers ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... people experience X-ray computed tomography (CT) scanners when they are evaluated ... of Dr. Quin Liu, PhD., in Wuhan China, rice plants were ... of an agriculture study to increase rice yield. Into the ... in an automated facility that could process 4,320 rice plants a ...
... Inspired by Mother Nature, scientists are reporting development of ... to survive in a dormant condition for long periods despite ... in Journal of the American Chemical Society , they ... that protect anthrax and certain other bacterial cells, making those ...
... known that landfills produce methane, but had a hard time ... as a friendly environment for the organisms that produce methane. ... species of microbe is paving the way for other methane ... called Methanosarcina barkeri appears to be the key ...
Cached Biology News:Seeing rice with X-rays may improve crop yields 2Researchers ID microbe responsible for methane from landfills 2
(Date:8/21/2014)... 2014 DNA vaccine pioneer Immunomic ... development of JRC-LAMP-vax, an innovative and safe potential treatment ... studies began this month in Hawaii, moving the world ... The Japanese red cedar releases pollen that causes devastating ... Cedar pollen wreaks similar havoc in Colorado, New Mexico ...
(Date:8/21/2014)... Emmetsburg, IA (PRWEB) August 21, 2014 ... Project LIBERTY Opening , The Court of His Majesty ... King will attend the Grand Opening of POET-DSM Advanced ... on Wednesday, Sept. 3. , The King will take ... formal opening activity, scheduled for 11 a.m.-12:20 p.m. and ...
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
(Date:8/21/2014)... 21, 2014 Gallus BioPharmaceuticals ... development and manufacturing organization (CMO) announced today that ... an oncology company focused on the development of ... manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal ... Under the agreement the antibody will be ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... Jennerex, Inc., a private clinical-stage biotherapeutics company focused on ... products for cancer, today presented preliminary data from a ... with advanced liver cancer showing a benefit in overall ... from the study HEP007 indicated that the risk of ...
... 19, 2011 Metabolex, Inc., a biopharmaceutical company focused ... for the treatment of metabolic diseases, announced today that ... arhalofenate (MBX-102), its product candidate for the management of ... double-blind, placebo-controlled study will evaluate the safety and urate-lowering ...
... May 19, 2011 Reportlinker.com announces that ... in its catalogue: Global ... This report analyzes the ... The report provides separate comprehensive analytics for ...
Cached Biology Technology:Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 2Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 3Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 4Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 5Metabolex Initiates Phase 2 Trial of Arhalofenate 2Global Biosimilars Industry 2Global Biosimilars Industry 3Global Biosimilars Industry 4Global Biosimilars Industry 5Global Biosimilars Industry 6Global Biosimilars Industry 7Global Biosimilars Industry 8Global Biosimilars Industry 9Global Biosimilars Industry 10